Recent Developments in Glioblastoma‐On‐A‐Chip for Advanced Drug Screening Applications

Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood‐brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro mo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Small (Weinheim an der Bergstrasse, Germany) Germany), 2025-01, Vol.21 (1), p.e2405511-n/a
Hauptverfasser:	Maity, Surjendu, Bhuyan, Tamanna, Jewell, Christopher, Kawakita, Satoru, Sharma, Saurabh, Nguyen, Huu Tuan, Hassani Najafabadi, Alireza, Ermis, Menekse, Falcone, Natashya, Chen, Junjie, Mandal, Kalpana, Khorsandi, Danial, Yilgor, Can, Choroomi, Auveen, Torres, Emily, Mecwan, Marvin, John, Johnson V., Akbari, Mohsen, Wang, Zhaohui, Moniz‐Garcia, Diogo, Quiñones‐Hinojosa, Alfredo, Jucaud, Vadim, Dokmeci, Mehmet Remzi, Khademhosseini, Ali
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Blood-Brain Barrier - metabolism Brain Brain Neoplasms - drug therapy disease modeling Drug Evaluation, Preclinical drug screening GBM GBM‐on‐a‐chip Glioblastoma - drug therapy Glioblastoma - pathology Heterogeneity Human tissues Humans Lab-On-A-Chip Devices tumor microenvironment Tumors Two dimensional models
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!